Regulators Insist On Large-Scale Trials For Coronavirus Treatment Candidates
Regulators Also Highlight Need To Preserve Supplies For Non-COVID-19 Uses
Executive Summary
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.
You may also be interested in...
WHO Member States Agree To Strengthen Global Clinical Trial Ecosystem
World Health Assembly delegates have given the thumbs up to a resolution that draws on lessons learnt during the COVID-19 pandemic to improve global coordination on how clinical trials are designed, evaluated and reported.
WHO Member States Agree To Strengthen Global Clinical Trial Ecosystem
World Health Assembly delegates have given the thumbs up to a resolution that draws on lessons learnt during the COVID-19 pandemic to improve global coordination on how clinical trials are designed, evaluated and reported.
Italy Opens Up On Trial Woes In A Pandemic
Italian medicines agency chief Nicola Magrini recounts the problems AIFA faced and the lessons it learned through its work at the height of the coronavirus outbreak in Italy.